Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675691 | 1.00 | SIGMAR1 (0.44) | SIGMAR1PDPK1ADORA2AADORA1CNR1 | |
| SCHEMBL5680214 | 1.00 | SIGMAR1 (0.44) | SIGMAR1PDPK1ADORA2AADORA1CNR1 | |
| SCHEMBL5675579 | 1.00 | SIGMAR1 (0.44) | SIGMAR1PDPK1ADORA2AADORA1CNR1 | |
| SCHEMBL22333426 | 0.81 | PDPK1 (0.58) | PDPK1SLC6A2SLC6A4ADRA2BADRA2C | |
| SCHEMBL20175248 | 0.80 | ADORA2A (0.43) | SIGMAR1ADORA2AADORA1CNR1PYGL | |
| SCHEMBL13761886 | 0.80 | ADORA2A (0.43) | SIGMAR1ADORA2AADORA1CNR1PYGL | |
| SCHEMBL13761888 | 0.80 | ADORA2A (0.43) | SIGMAR1ADORA2AADORA1CNR1PYGL | |
| SCHEMBL5677126 | 0.80 | ADORA2A (0.40) | SIGMAR1ADORA2AADORA1CNR1PYGL | |
| SCHEMBL12362858 | 0.80 | ADORA2A (0.43) | SIGMAR1ADORA2AADORA1CNR1PYGL | |
| SCHEMBL5677122 | 0.80 | ADORA2A (0.40) | SIGMAR1ADORA2AADORA1CNR1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009037416-A1 | PROCESS FOR PREPARING SULPHONAMIDES | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| EP-1414426-B1 | CARBOCYCLIC HYDRAZINO INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORP (FI) | 2006-03-01 | — | — | EP | disclosed |
| US-6982286-B2 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORP. (FI) | 2006-01-03 | — | — | US | disclosed |
| US-20040236108-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| EP-1414426-A1 | CARBOCYCLIC HYDRAZINO INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | Biotie Therapies Corp. (FI) | 2004-05-06 | — | — | EP | disclosed |
| US-20030125360-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORP. | 2003-07-03 | — | — | US | disclosed |
| WO-2003006003-A1 | CARBOCYCLIC HYDRAZINO INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
| US-5773463-A | DECALCIFICATION OF BRAIN DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0711272-A1 | INDANE AND TETRAHYDRONAPHTHALENE DERIVATIVES AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004028-A1 | INDANE AND TETRAHYDRONAPHTHALENE DERIVATIVES AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | disclosed |
| EP-0080117-B1 | THE (R,R)-ENANTIOMER OF TRANS-INDENO(1,2-B)-1,4-OXAZINES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING IT | MERCK & CO. INC. (US) | 1987-12-02 | — | — | EP | disclosed |
| US-4431647-A | PARKINSON'S DISEASE | MERCK & CO., INC. (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0080117-A2 | The (R,R)-enantiomer of trans-indeno(1,2-b)-1,4-oxazines, process for its preparation and pharmaceutical formulation containing it | MERCK & CO. INC. (US) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236108-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | AOC2, VCAM1, AOC3 | SIGMAR1 397/4885PDPK1 1705/4885ADORA2A 3307/4885 |
| US-20030125360-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | AOC2, AOC3, AOC1 | SIGMAR1 319/4885PDPK1 1960/4885ADORA2A 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.